APO Research
Talk to an analyst

APO RESEARCH · REPORT

Direct Acting Antivirals

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Direct Acting Antivirals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025196 pages

Choose your research edition.

Industry ResearchDirect Acting Antivirals Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Direct Acting Antivirals Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Direct Acting Antivirals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Direct Acting Antivirals Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Direct Acting Antivirals Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Direct Acting Antivirals market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Direct Acting Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Direct Acting Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Direct Acting Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Direct Acting Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Direct Acting Antivirals include AbbVie, Asegua Therapeutics, Bristol Myers Squibb, Gilead Sciences, Merck, Ascletis Pharma, Cosunter pharmaceutical, Kawin Technology and Sanhome Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Direct Acting Antivirals market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Direct Acting Antivirals and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Direct Acting Antivirals sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Direct Acting Antivirals market size, projected growth trends, production technologies, key applications, and end-use industries.

Direct Acting Antivirals Segment by Company

AbbVie

Asegua Therapeutics

Bristol Myers Squibb

Gilead Sciences

Merck

Ascletis Pharma

Cosunter pharmaceutical

Kawin Technology

Sanhome Pharmaceutical

Beijing Sihuan Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Direct Acting Antivirals Segment by Type

Pangenotypic

Genotype-Specific

Direct Acting Antivirals Segment by Application

Hospital and Clinic

Pharmacy

Other

Direct Acting Antivirals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Acting Antivirals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Direct Acting Antivirals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Acting Antivirals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Direct Acting Antivirals market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Direct Acting Antivirals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Direct Acting Antivirals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Direct Acting Antivirals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Direct Acting Antivirals Industry Trends Table 2. Direct Acting Antivirals Industry Drivers Table 3. Direct Acting Antivirals Industry Opportunities and Challenges Table 4. Direct Acting Antivirals Industry Restraints Table 5. Global Direct Acting Antivirals Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Direct Acting Antivirals Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Direct Acting Antivirals Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Direct Acting Antivirals Sales Market Share by Manufacturers Table 9. Global Direct Acting Antivirals Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Direct Acting Antivirals Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Direct Acting Antivirals Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Direct Acting Antivirals Manufacturers, Product Type & Application Table 13. Global Direct Acting Antivirals Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Direct Acting Antivirals by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Pangenotypic Table 17. Major Manufacturers of Genotype-Specific Table 18. Global Direct Acting Antivirals Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Direct Acting Antivirals Sales by Type (2021-2026) & (K Units) Table 20. Global Direct Acting Antivirals Sales by Type (2027-2032) & (K Units) Table 21. Global Direct Acting Antivirals Sales Market Share by Type (2021-2026) Table 22. Global Direct Acting Antivirals Sales Market Share by Type (2027-2032) Table 23. Global Direct Acting Antivirals Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Direct Acting Antivirals Revenue by Type (2021-2026) & (K Units) Table 25. Global Direct Acting Antivirals Revenue by Type (2027-2032) & (K Units) Table 26. Global Direct Acting Antivirals Revenue Market Share by Type (2021-2026) Table 27. Global Direct Acting Antivirals Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital and Clinic Table 29. Major Manufacturers of Pharmacy Table 30. Major Manufacturers of Other Table 31. Global Direct Acting Antivirals Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Direct Acting Antivirals Sales by Application (2021-2026) & (K Units) Table 33. Global Direct Acting Antivirals Sales by Application (2027-2032) & (K Units) Table 34. Global Direct Acting Antivirals Sales Market Share by Application (2021-2026) Table 35. Global Direct Acting Antivirals Sales Market Share by Application (2027-2032) Table 36. Global Direct Acting Antivirals Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Direct Acting Antivirals Revenue by Application (2021-2026) & (K Units) Table 38. Global Direct Acting Antivirals Revenue by Application (2027-2032) & (K Units) Table 39. Global Direct Acting Antivirals Revenue Market Share by Application (2021-2026) Table 40. Global Direct Acting Antivirals Revenue Market Share by Application (2027-2032) Table 41. Global Direct Acting Antivirals Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Direct Acting Antivirals Sales by Region (2021-2026) & (K Units) Table 43. Global Direct Acting Antivirals Sales Market Share by Region (2021-2026) Table 44. Global Direct Acting Antivirals Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Direct Acting Antivirals Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Direct Acting Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Direct Acting Antivirals Sales by Country (2021-2026) & (K Units) Table 48. North America Direct Acting Antivirals Sales by Country (2027-2032) & (K Units) Table 49. Europe Direct Acting Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Direct Acting Antivirals Sales by Country (2021-2026) & (K Units) Table 51. Europe Direct Acting Antivirals Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Direct Acting Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Direct Acting Antivirals Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Direct Acting Antivirals Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Direct Acting Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Direct Acting Antivirals Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Direct Acting Antivirals Sales by Country (2027-2032) & (K Units) Table 58. Global Direct Acting Antivirals Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Direct Acting Antivirals Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Direct Acting Antivirals Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Direct Acting Antivirals Revenue Market Share by Region (2021-2026) Table 62. Global Direct Acting Antivirals Revenue Market Share by Region (2027-2032) Table 63. AbbVie Company Information Table 64. AbbVie Business Overview Table 65. AbbVie Direct Acting Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. AbbVie Direct Acting Antivirals Product Portfolio Table 67. AbbVie Recent Development Table 68. Asegua Therapeutics Company Information Table 69. Asegua Therapeutics Business Overview Table 70. Asegua Therapeutics Direct Acting Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Asegua Therapeutics Direct Acting Antivirals Product Portfolio Table 72. Asegua Therapeutics Recent Development Table 73. Bristol Myers Squibb Company Information Table 74. Bristol Myers Squibb Business Overview Table 75. Bristol Myers Squibb Direct Acting Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Bristol Myers Squibb Direct Acting Antivirals Product Portfolio Table 77. Bristol Myers Squibb Recent Development Table 78. Gilead Sciences Company Information Table 79. Gilead Sciences Business Overview Table 80. Gilead Sciences Direct Acting Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Gilead Sciences Direct Acting Antivirals Product Portfolio Table 82. Gilead Sciences Recent Development Table 83. Merck Company Information Table 84. Merck Business Overview Table 85. Merck Direct Acting Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Merck Direct Acting Antivirals Product Portfolio Table 87. Merck Recent Development Table 88. Ascletis Pharma Company Information Table 89. Ascletis Pharma Business Overview Table 90. Ascletis Pharma Direct Acting Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Ascletis Pharma Direct Acting Antivirals Product Portfolio Table 92. Ascletis Pharma Recent Development Table 93. Cosunter pharmaceutical Company Information Table 94. Cosunter pharmaceutical Business Overview Table 95. Cosunter pharmaceutical Direct Acting Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Cosunter pharmaceutical Direct Acting Antivirals Product Portfolio Table 97. Cosunter pharmaceutical Recent Development Table 98. Kawin Technology Company Information Table 99. Kawin Technology Business Overview Table 100. Kawin Technology Direct Acting Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Kawin Technology Direct Acting Antivirals Product Portfolio Table 102. Kawin Technology Recent Development Table 103. Sanhome Pharmaceutical Company Information Table 104. Sanhome Pharmaceutical Business Overview Table 105. Sanhome Pharmaceutical Direct Acting Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Sanhome Pharmaceutical Direct Acting Antivirals Product Portfolio Table 107. Sanhome Pharmaceutical Recent Development Table 108. Beijing Sihuan Pharmaceutical Company Information Table 109. Beijing Sihuan Pharmaceutical Business Overview Table 110. Beijing Sihuan Pharmaceutical Direct Acting Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Beijing Sihuan Pharmaceutical Direct Acting Antivirals Product Portfolio Table 112. Beijing Sihuan Pharmaceutical Recent Development Table 113. YiChang HEC ChangJiang Pharmaceutical Company Information Table 114. YiChang HEC ChangJiang Pharmaceutical Business Overview Table 115. YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Product Portfolio Table 117. YiChang HEC ChangJiang Pharmaceutical Recent Development Table 118. Chia Tai Tianqing Pharmaceutical Company Information Table 119. Chia Tai Tianqing Pharmaceutical Business Overview Table 120. Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Product Portfolio Table 122. Chia Tai Tianqing Pharmaceutical Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. Direct Acting Antivirals Distributors List Table 126. Direct Acting Antivirals Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Direct Acting Antivirals Product Image Figure 2. Global Direct Acting Antivirals Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Direct Acting Antivirals Market Size (2021-2032) & (US$ Million) Figure 4. Global Direct Acting Antivirals Sales (2021-2032) & (K Units) Figure 5. Global Direct Acting Antivirals Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Direct Acting Antivirals Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Pangenotypic Image Figure 9. Genotype-Specific Image Figure 10. Global Direct Acting Antivirals Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Direct Acting Antivirals Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Direct Acting Antivirals Sales Market Share by Type (2021-2032) Figure 13. Global Direct Acting Antivirals Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Direct Acting Antivirals Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Direct Acting Antivirals Revenue Market Share by Type (2021-2032) Figure 16. Hospital and Clinic Image Figure 17. Pharmacy Image Figure 18. Other Image Figure 19. Global Direct Acting Antivirals Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Direct Acting Antivirals Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Direct Acting Antivirals Sales Market Share by Application (2021-2032) Figure 22. Global Direct Acting Antivirals Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Direct Acting Antivirals Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Direct Acting Antivirals Revenue Market Share by Application (2021-2032) Figure 25. North America Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Direct Acting Antivirals Sales Market Share by Country (2021-2032) Figure 27. U.S. Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Direct Acting Antivirals Sales Market Share by Country (2021-2032) Figure 32. Germany Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Direct Acting Antivirals Sales Market Share by Country (2021-2032) Figure 39. China Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Direct Acting Antivirals Sales Market Share by Country (2021-2032) Figure 47. Brazil Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Direct Acting Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Direct Acting Antivirals Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Direct Acting Antivirals Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Direct Acting Antivirals Revenue (2021-2032) & (US$ Million) Figure 58. North America Direct Acting Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Direct Acting Antivirals Revenue (2021-2032) & (US$ Million) Figure 60. Europe Direct Acting Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Direct Acting Antivirals Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Direct Acting Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Direct Acting Antivirals Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Direct Acting Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Direct Acting Antivirals Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Direct Acting Antivirals Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Pangenotypic
  • Genotype-Specific
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • AbbVie
  • Asegua Therapeutics
  • Bristol Myers Squibb
  • Gilead Sciences
  • Merck
  • Ascletis Pharma
  • Cosunter pharmaceutical
  • Kawin Technology
  • Sanhome Pharmaceutical
  • Beijing Sihuan Pharmaceutical
  • YiChang HEC ChangJiang Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Direct Acting Antivirals Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Direct Acting Antivirals Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Direct Acting Antivirals Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Direct Acting Antivirals Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Direct Acting Antivirals Market Dynamics
  1. 2.1 Direct Acting Antivirals Industry Trends
  2. 2.2 Direct Acting Antivirals Industry Drivers
  3. 2.3 Direct Acting Antivirals Industry Opportunities and Challenges
  4. 2.4 Direct Acting Antivirals Industry Restraints
3 Direct Acting Antivirals Market by Manufacturers
  1. 3.1 Global Direct Acting Antivirals Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Direct Acting Antivirals Sales by Manufacturers (2021-2026)
  3. 3.3 Global Direct Acting Antivirals Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Direct Acting Antivirals Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Direct Acting Antivirals Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Direct Acting Antivirals Manufacturers, Product Type & Application
  7. 3.7 Global Direct Acting Antivirals Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Direct Acting Antivirals Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Direct Acting Antivirals Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Direct Acting Antivirals Tier 1, Tier 2, and Tier 3
4 Direct Acting Antivirals Market by Type
  1. 4.1 Direct Acting Antivirals Type Introduction
  2. 4.1.1 Pangenotypic
  3. 4.1.2 Genotype-Specific
  4. 4.2 Global Direct Acting Antivirals Sales by Type
  5. 4.2.1 Global Direct Acting Antivirals Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Direct Acting Antivirals Sales by Type (2021-2032)
  7. 4.2.3 Global Direct Acting Antivirals Sales Market Share by Type (2021-2032)
  8. 4.3 Global Direct Acting Antivirals Revenue by Type
  9. 4.3.1 Global Direct Acting Antivirals Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Direct Acting Antivirals Revenue by Type (2021-2032)
  11. 4.3.3 Global Direct Acting Antivirals Revenue Market Share by Type (2021-2032)
5 Direct Acting Antivirals Market by Application
  1. 5.1 Direct Acting Antivirals Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Direct Acting Antivirals Sales by Application
  6. 5.2.1 Global Direct Acting Antivirals Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Direct Acting Antivirals Sales by Application (2021-2032)
  8. 5.2.3 Global Direct Acting Antivirals Sales Market Share by Application (2021-2032)
  9. 5.3 Global Direct Acting Antivirals Revenue by Application
  10. 5.3.1 Global Direct Acting Antivirals Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Direct Acting Antivirals Revenue by Application (2021-2032)
  12. 5.3.3 Global Direct Acting Antivirals Revenue Market Share by Application (2021-2032)
6 Global Direct Acting Antivirals Sales by Region
  1. 6.1 Global Direct Acting Antivirals Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Direct Acting Antivirals Sales by Region (2021-2032)
  3. 6.2.1 Global Direct Acting Antivirals Sales by Region (2021-2026)
  4. 6.2.2 Global Direct Acting Antivirals Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Direct Acting Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Direct Acting Antivirals Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Direct Acting Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Direct Acting Antivirals Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Direct Acting Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Direct Acting Antivirals Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Direct Acting Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Direct Acting Antivirals Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Direct Acting Antivirals Revenue by Region
  1. 7.1 Global Direct Acting Antivirals Revenue by Region
  2. 7.1.1 Global Direct Acting Antivirals Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Direct Acting Antivirals Revenue by Region (2021-2026)
  4. 7.1.3 Global Direct Acting Antivirals Revenue by Region (2027-2032)
  5. 7.1.4 Global Direct Acting Antivirals Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Direct Acting Antivirals Revenue (2021-2032)
  8. 7.2.2 North America Direct Acting Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Direct Acting Antivirals Revenue (2021-2032)
  11. 7.3.2 Europe Direct Acting Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Direct Acting Antivirals Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Direct Acting Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Direct Acting Antivirals Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Direct Acting Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AbbVie
  2. 8.1.1 AbbVie Company Information
  3. 8.1.2 AbbVie Business Overview
  4. 8.1.3 AbbVie Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie Direct Acting Antivirals Product Portfolio
  6. 8.1.5 AbbVie Recent Developments
  7. 8.2 Asegua Therapeutics
  8. 8.2.1 Asegua Therapeutics Company Information
  9. 8.2.2 Asegua Therapeutics Business Overview
  10. 8.2.3 Asegua Therapeutics Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Asegua Therapeutics Direct Acting Antivirals Product Portfolio
  12. 8.2.5 Asegua Therapeutics Recent Developments
  13. 8.3 Bristol Myers Squibb
  14. 8.3.1 Bristol Myers Squibb Company Information
  15. 8.3.2 Bristol Myers Squibb Business Overview
  16. 8.3.3 Bristol Myers Squibb Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol Myers Squibb Direct Acting Antivirals Product Portfolio
  18. 8.3.5 Bristol Myers Squibb Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences Direct Acting Antivirals Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Direct Acting Antivirals Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Ascletis Pharma
  32. 8.6.1 Ascletis Pharma Company Information
  33. 8.6.2 Ascletis Pharma Business Overview
  34. 8.6.3 Ascletis Pharma Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ascletis Pharma Direct Acting Antivirals Product Portfolio
  36. 8.6.5 Ascletis Pharma Recent Developments
  37. 8.7 Cosunter pharmaceutical
  38. 8.7.1 Cosunter pharmaceutical Company Information
  39. 8.7.2 Cosunter pharmaceutical Business Overview
  40. 8.7.3 Cosunter pharmaceutical Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Cosunter pharmaceutical Direct Acting Antivirals Product Portfolio
  42. 8.7.5 Cosunter pharmaceutical Recent Developments
  43. 8.8 Kawin Technology
  44. 8.8.1 Kawin Technology Company Information
  45. 8.8.2 Kawin Technology Business Overview
  46. 8.8.3 Kawin Technology Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kawin Technology Direct Acting Antivirals Product Portfolio
  48. 8.8.5 Kawin Technology Recent Developments
  49. 8.9 Sanhome Pharmaceutical
  50. 8.9.1 Sanhome Pharmaceutical Company Information
  51. 8.9.2 Sanhome Pharmaceutical Business Overview
  52. 8.9.3 Sanhome Pharmaceutical Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sanhome Pharmaceutical Direct Acting Antivirals Product Portfolio
  54. 8.9.5 Sanhome Pharmaceutical Recent Developments
  55. 8.10 Beijing Sihuan Pharmaceutical
  56. 8.10.1 Beijing Sihuan Pharmaceutical Company Information
  57. 8.10.2 Beijing Sihuan Pharmaceutical Business Overview
  58. 8.10.3 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Product Portfolio
  60. 8.10.5 Beijing Sihuan Pharmaceutical Recent Developments
  61. 8.11 YiChang HEC ChangJiang Pharmaceutical
  62. 8.11.1 YiChang HEC ChangJiang Pharmaceutical Company Information
  63. 8.11.2 YiChang HEC ChangJiang Pharmaceutical Business Overview
  64. 8.11.3 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Product Portfolio
  66. 8.11.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments
  67. 8.12 Chia Tai Tianqing Pharmaceutical
  68. 8.12.1 Chia Tai Tianqing Pharmaceutical Company Information
  69. 8.12.2 Chia Tai Tianqing Pharmaceutical Business Overview
  70. 8.12.3 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Product Portfolio
  72. 8.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Direct Acting Antivirals Value Chain Analysis
  2. 9.1.1 Direct Acting Antivirals Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Direct Acting Antivirals Production Mode & Process
  6. 9.2 Direct Acting Antivirals Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Direct Acting Antivirals Distributors
  9. 9.2.3 Direct Acting Antivirals Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst